Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05805358

Hyperpolarized 13C MRI for Cancer Immunotherapy (DNPSPIO)

Next Generation Precision Imaging for Cancer Immunotherapy: Dynamic Nuclear Polarization and Metabolomics Study

Sponsor: Chang Gung Memorial Hospital

Conditions Cervical Cancer Endometrial Cancer Gynecologic Cancer Ovarian Cancer

Interventions Hyperpolarized 13C-Pyruvate injection

Updated 5 times since 2023 Last updated: Aug 28, 2023 Started: Nov 1, 2023 Primary completion: Jul 31, 2026 Completion: Jul 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cervical Cancer and Endometrial Cancer, this trial is actively recruiting participants. The trial is conducted by Chang Gung Memorial Hospital and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Not Yet Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Sep 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
May 2023 — Sep 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chang Gung Memorial Hospital
National Science and Technology Council

Data source: Chang Gung Memorial Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taoyuan, Taiwan